The new collaborative database of failed Alzheimer’s disease clinical trials spearheaded by the Coalition Against Major Diseases
has many in the pharmaceutical industry excited.
“by sharing information about our projects, could we improve the way we may diagnose, the way we may monitor and the way we may predict outcomes to make regulatory approval and development much easier,” Paul Chew, chief medical officer of Sanofi U.S., tells the Health Blog.
Michael Gold, of GlaxoSmithKline’s Neurosciences Medicine Development Cente
Either we fix the methodology or publicly owned companies will invest in medicines that have a greater rate of return.
Johnson & Johnson’s Sheldon Sloan
this is aligned with our R&D strategy to engage in novel partnerships and collaborations that bring speed, efficiency, safety and predictability to the development of innovative medical solutions for patients